<DOC>
	<DOCNO>NCT00035815</DOCNO>
	<brief_summary>The purpose multicenter study determine insulin-like growth factor-1 ( IGF-I ) slow progressive weakness amyotrophic lateral sclerosis ( ALS ) patient . Study participant follow 2 year enrol . They receive either placebo active IGF-I . Examinations take place approximately 6-month interval .</brief_summary>
	<brief_title>Insulin-like Growth Factor-1 Amyotrophic Lateral Sclerosis ( ALS ) Trial</brief_title>
	<detailed_description>The objective trial determine whether IGF-1 ( MyotrophinTM ) slow progression weakness amyotrophic lateral sclerosis ( ALS ) . Three hundred thirty patient ALS 20 medical center participate double blind , placebo-controlled two-year study . Half patient receive IGF-1 half receive placebo . The drug administer twice day . ALS neurodegenerative disorder cause progressive muscle weakness loss motor neuron . IGF-1 neurotrophic factor essential normal development nervous system show protection motor neuron animal model cell culture system . It think block cell death pathway promote muscle re-innervation axonal growth regeneration .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion Criteria Patients enter study : Are age 1880 year old . Legal resident United States Canada . Have history chronic onset progressive motor weakness le 24 month duration . Fulfill El Escorial criterion probable definite ALS . If female , surgically sterile , two year postmenopausal , childbearing potential , must use medically acceptable method birth control agree continue use method duration study . Acceptable method include barrier method spermicide , oral contraceptive ( normal dos acceptable ; low dose oral contraceptive contraceptive implant must use barrier method ) , intrauterine device ( IUD ) , abstinence . Have negative pregnancy test . Are able comply protocol requirement . Can provide write informed consent . Have manual muscle test score less 8 . Have force vital capacity pulmonary function test *60 % predict . Patients enter study : Have follow condition : renal disease ( Creatine &gt; 2.0 ) active systemic disease Have clinically significant abnormality prestudy laboratory evaluation , physical examination , ECG , chest xray ophthalmologic exam . Have clinically significant medical condition ( e.g. , within six month baseline , myocardial infarction , angina pectoris , and/or congestive heart failure ) , opinion investigator , would compromise safety patient . Have Type I Type II diabetes . Have history cancer include melanoma exception localize skin cancer ( evidence metastasis , significant invasion , reoccurrence within three year baseline ) carcinoma insitu cervix ( woman ) . Have use investigational drug within 30 day baseline visit . Have tracheostomy . Have Beck 's Depression Inventory score * 12 . Have legal residency outside United States Canada . Be pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>progressive weakness</keyword>
	<keyword>insulin-like growth factor-1</keyword>
	<keyword>IGF-I</keyword>
	<keyword>Myotrophin</keyword>
</DOC>